Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study.

Date publication

novembre 2016

Journal

International journal of radiation oncology, biology, physics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERNIER-CHASTAGNER Valérie

Tous les auteurs :
Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, Azria D, Beckendorf V, Suchaud JP, Bernier V, Perol D, Carrie C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27788949

Résumé

To report the long-term results of the French Genitourinary Study Group (GETUG)-01 study in terms of event-free survival (EFS) and overall survival (OS) and assess the potential interaction between hormonotherapy and pelvic nodes irradiation.

Mots clés

Aged, Antineoplastic Agents, Hormonal, therapeutic use, Disease-Free Survival, Dose Fractionation, Follow-Up Studies, France, Gonadotropin-Releasing Hormone, agonists, Humans, Lymphatic Irradiation, methods, Male, Neoplasm Grading, Neoplasm Recurrence, Local, blood, Neoplasm Staging, Pelvis, Prostate-Specific Antigen, blood, Prostatic Neoplasms, drug therapy, Radiotherapy, Conformal, methods, Time Factors

Référence

Int. J. Radiat. Oncol. Biol. Phys.. 2016 11 15;96(4):759-769